Prana Biotechnology Limited

Biotechnology company commences phase I clinical trial of PBT2

Published in Elder Law Weekly, April 13th, 2005

Prana Biotechnology Limited (PRAN, ASX, PBT) announced that it has commenced the phase I clinical trial of PBT2 with the dosing of its first subject at a facility associated with the Utrecht University Hospital in Utrecht, The Netherlands.

The phase I clinical trial is the first of a planned series of studies examining the safety and pharmacokinetics of PBT2 in normal human volunteers.

PBT2 is the first completely Prana-discovered compound, and is the successor to PBT1 for the treatment of Alzheimer disease. PBT2 is designed to have an improved safety and efficacy profile compared to PBT1. The compound has demonstrated significantly greater...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2005-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry